Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.71 |
| ▸ | MEN1 | O00255 | 8/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.71 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888051 | 1.00 | MAPT (0.71) | MAPTMEN1KMT2AMAPK1TAS2R14 | |
| SCHEMBL6878510 | 0.84 | PTPN1 (0.56) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL6878505 | 0.84 | PTPN1 (0.56) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL6885684 | 0.84 | MAPT (0.66) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL6885682 | 0.84 | MAPT (0.66) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL17319547 | 0.81 | TAS2R14 (0.81) | MAPTMEN1KMT2AMAPK1TAS2R14 | |
| SCHEMBL6887142 | 0.80 | MEN1 (0.78) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL6887140 | 0.80 | MEN1 (0.78) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL7898031 | 0.80 | MAPT (0.59) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL1279501 | 0.80 | TAS2R14 (1.00) | MAPTMEN1KMT2AMAPK1TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673816-B1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | Esswein, Angelika (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD | 2003-02-13 | — | — | US | disclosed |
| EP-1117655-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | Esswein, Angelika (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018747-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | NR1H4, NR1D1, NR1I2 | MAPT 3886/4885MEN1 838/4885KMT2A 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.